Translating Molecular Advances in Fragile X Syndrome Into Therapy: A Review

Randi J. Hagerman, MD; Vincent Des-Portes, MD, PhD; Fabrizio Gasparini, PhD; Sébastien Jacquemont, MD; and Baltazar Gomez-Mancilla, MD, PhD

Published: April 15, 2014

Article Abstract

Fragile X syndrome is an inherited disease with cognitive, behavioral, and neurologic manifestations, resulting from a single genetic mutation. A variety of treatments that target individual symptoms of fragile X syndrome are currently utilized with limited efficacy. Research in animal models has resulted in the development of potential novel pharmacologic treatments that target the underlying molecular defect in fragile X syndrome, rather than the resultant symptoms. This review describes recent advances in our understanding of the molecular basis of fragile X syndrome and summarizes the ongoing clinical research programs.

J Clin Psychiatry 2014;75(4):e294-e307

Submitted: August 5, 2013; accepted January 16, 2014 (doi:10.4088/JCP.13r08714).

Corresponding author: Baltazar Gomez-Mancilla, MD, PhD, Department of Neuroscience, Translational Medicine, Novartis Institutes of Biomedical Research, WSJ.210.25.5, CH-4056 Basel, Switzerland (

Volume: 75

Quick Links: Psychiatry

Continue Reading…

Subscribe to read the entire article


Buy this Article as a PDF


Sign-up to stay
up-to-date today!


Already registered? Sign In

Original Research

Sublingual Dexmedetomidine for the Treatment of Acute Agitation in Adults With Schizophrenia or Schizoaffective Disorder: A Randomized Placebo-Controlled Trial

This RCT determined whether a single dose of sublingual dexmedetomidine reduced acute agitation associated with schizophrenia or...